Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 01, 2023 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program

SAN DIEGO and SHANGHAI, China, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the...
January 25, 2023 07:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive candidiasis in over a decade ...
January 04, 2023 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
December 01, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
November 29, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
November 28, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care dosed once-daily Rezafungin PDUFA target action date is scheduled for March 22, 2023 SAN DIEGO...
November 23, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Participate in the World Antiviral Congress 2022

SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
November 08, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present at the Stifel Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
November 03, 2022 17:47 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
October 17, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...